Xlife Sciences Collaborates with Hovione for Gene Therapy in Liver Cancer

Xlife Sciences AG has announced a strategic partnership between its portfolio company, Firstgene Life Sciences GmbH, and Hovione S.A. The collaboration focuses on developing a novel gene therapy for hepatocellular carcinoma (HCC), a type of liver cancer with significant unmet medical need.

This partnership involves utilizing Hovione's gene therapy platform to create a tissue-specific treatment for HCC. With around 900,000 new cases each year, and a low survival rate, this illness demands innovative solutions. Hovione's platform aims to tackle conventional gene therapy challenges such as off-target effects, offering targeted genetic material delivery.

Through this alliance, Xlife Sciences seeks to expand its presence in the gene therapy field, leveraging synergies with existing portfolio firms. This move strengthens its business model, which bridges early-stage biotech innovation with established industrial applications. It marks a significant entry into a high-potential therapeutic area.